Trends in allogeneic hematopoietic cell transplantation survival using population-based descriptive epidemiology method: analysis of national transplant registry data.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
received:
07
11
2023
accepted:
31
05
2024
revised:
02
05
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
Prognosis for patients undergoing hematopoietic cell transplantation (HCT) has been improving. Short-term survival information, such as crude survival rates that consider deaths immediately after the transplantation, may not be sufficiently useful for assessing long-term survival. Using the data of the Japanese HCT registry, the net survival rate of patients who survived for a given period was determined according to age, disease, and type of transplant. We included a total of 41,716 patients who received their first allogeneic hematopoietic cell transplantation between 1991 and 2015. For each disease, age group, graft source subcategory, net survival was calculated using the Pohar-Perme method, and 5-year conditional net survival (CS) was calculated. Ten-year net survivals of total patient cohort were 41.5% and 47.4% for males and females, respectively. Except for myelodysplastic syndrome, multiple myeloma, and adult T-cell leukemia/lymphoma, 5-year CS for 5-year transplant survivors exceeded 90%. CS was especially high for aplastic anemia, of which was over 100% for children and younger adults receiving cord blood, suggesting that these patients have similar longevity to an equivalent group from the general population. These findings provide useful information for long-term survival, and can serve as benchmark for comparisons among registries, including other cancers.
Identifiants
pubmed: 38898226
doi: 10.1038/s41409-024-02326-y
pii: 10.1038/s41409-024-02326-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 17K08911
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 22K10360
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Bhatia S, Dai C, Landier W, Hageman L, Wu J, Schlichting E, et al. Trends in late mortality and life expectancy after allogeneic blood or marrow transplantation over 4 decades: a blood or marrow transplant survivor study report. JAMA Oncol. 2021;7:1626–34.
pubmed: 34499078
doi: 10.1001/jamaoncol.2021.3676
Tanaka Y, Kurosawa S, Tajima K, Tanaka T, Ito R, Inoue Y, et al. Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:553–9.
pubmed: 26752142
doi: 10.1038/bmt.2015.330
Konuma T, Mizuno S, Kondo T, Arai Y, Uchida N, Takahashi S, et al. Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. Blood Cancer J. 2022;12:81.
pubmed: 35614057
pmcid: 9132934
doi: 10.1038/s41408-022-00678-6
Yanada M, Masuko M, Mori J, Aoki J, Mizuno S, Fukuda T, et al. Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades. Bone Marrow Transplant. 2019;54:578–86.
pubmed: 30108330
doi: 10.1038/s41409-018-0301-7
Konuma T, Itonaga H, Ishiyama K, Hamamura A, Uchida N, Ozawa Y, et al. Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a real-world registry study in Japan. Am J Hematol. 2023;98:E68–71.
pubmed: 36633538
doi: 10.1002/ajh.26839
Shouval R, Fein JA, Labopin M, Kroger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573–84.
pubmed: 31477550
doi: 10.1016/S2352-3026(19)30158-9
Ohbiki M, Ito Y, Inamoto Y, Miyamura K, Uchida N, Fukuda T, et al. Improved long-term net survival after allogeneic hematopoietic cell transplantation in patients with hematologic malignancies over two decades. Transpl Cell Ther. 2023;29:768.e761–10.
doi: 10.1016/j.jtct.2023.09.010
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.
pubmed: 16641398
doi: 10.1056/NEJMra052638
Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2015;45:884–91.
pubmed: 26142437
doi: 10.1093/jjco/hyv088
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.
pubmed: 29395269
pmcid: 5879496
doi: 10.1016/S0140-6736(17)33326-3
Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 2014;105:1480–6.
pubmed: 25183551
pmcid: 4462379
doi: 10.1111/cas.12525
Okuyama A, Shibata A, Nishimoto H. Critical points for interpreting patients’ survival rate using cancer registries: a literature review. J Epidemiol. 2018;28:61–6.
pubmed: 29093355
pmcid: 5792228
doi: 10.2188/jea.JE20160180
Pohar Perme M, Esteve J, Rachet B. Analysing population-based cancer survival—settling the controversies. BMC Cancer. 2016;16:933.
pubmed: 27912732
pmcid: 5135814
doi: 10.1186/s12885-016-2967-9
Roche L, Danieli C, Belot A, Grosclaude P, Bouvier AM, Velten M, et al. Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods. Int J Cancer. 2013;132:2359–69.
pubmed: 22961565
doi: 10.1002/ijc.27830
Atsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R, et al. Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22:1702–9.
pubmed: 27246369
doi: 10.1016/j.bbmt.2016.05.019
Kliman D, Nivison-Smith I, Gottlieb D, Hamad N, Kerridge I, Purtill D, et al. Hematopoietic stem cell transplant recipients surviving at least 2 years from transplant have survival rates approaching population levels in the modern era of transplantation. Biol Blood Marrow Transplant. 2020;26:1711–8.
pubmed: 32194285
doi: 10.1016/j.bbmt.2020.03.005
Vanderwalde AM, Sun CL, Laddaran L, Francisco L, Armenian S, Berano-Teh J, et al. Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies. Leukemia. 2013;27:1139–45.
pubmed: 23183426
doi: 10.1038/leu.2012.311
Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge O, et al. Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. Haematologica. 2015;100:e240–3.
pubmed: 25682605
pmcid: 4450639
doi: 10.3324/haematol.2014.119214
Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant. 2001;28:909–15.
pubmed: 11753543
doi: 10.1038/sj.bmt.1703260
Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230–9.
pubmed: 21464398
pmcid: 3107742
doi: 10.1200/JCO.2010.33.7212
Assouline S, Li S, Gisselbrecht C, Fogarty P, Hay A, van den Neste E, et al. The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. Blood Adv. 2020;4:2011–7.
pubmed: 32396614
pmcid: 7218426
doi: 10.1182/bloodadvances.2020001646
Abdallah NH, Smith AN, Geyer S, Binder M, Greipp PT, Kapoor P, et al. Conditional survival in multiple myeloma and impact of prognostic factors over time. Blood Cancer J. 2023;13:78.
pubmed: 37188699
pmcid: 10185675
doi: 10.1038/s41408-023-00852-4
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367:1487–96.
pubmed: 23075175
doi: 10.1056/NEJMoa1203517
Jo T, Arai Y, Kondo T, Mizuno S, Hirabayashi S, Inamoto Y, et al. Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. Cytotherapy. 2022;24:1013–25.
pubmed: 35729020
doi: 10.1016/j.jcyt.2022.05.009
Kuwatsuka Y, Kanda J, Yamazaki H, Mori T, Miyamura K, Kako S, et al. A comparison of outcomes for cord blood transplantation and unrelated bone marrow transplantation in adult aplastic anemia. Biol Blood Marrow Transplant. 2016;22:1836–43.
pubmed: 27401034
doi: 10.1016/j.bbmt.2016.07.002
Smith AR, Wagner JE. Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol. 2009;147:246–61.
pubmed: 19796274
pmcid: 2782564
doi: 10.1111/j.1365-2141.2009.07828.x
Nagamine CML, Goulart BNG, Ziegelmann PK. Net survival in survival analyses for patients with cancer: a scoping review. Cancers. 2022;14:3304.
Atsuta Y. Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.
pubmed: 26547570
doi: 10.1007/s12185-015-1894-x
Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103:11–19.
pubmed: 26588927
doi: 10.1007/s12185-015-1907-9
Kuwatsuka Y. Quality control and assurance in hematopoietic stem cell transplantation data registries in Japan and other countries. Int J Hematol. 2016;103:20–24.
pubmed: 26563189
doi: 10.1007/s12185-015-1896-8
Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269–74.
pubmed: 17988995
doi: 10.1532/IJH97.06239
Atsuta Y. [The Japanese Transplant Registry Unified Management Program (TRUMP((R))): current issues and the future]. [Rinsho ketsueki] Jpn J Clin Hematol. 2020;61:387–91.
Ssenyonga, Stiller N, Nakata KC, Shalkow J, Redmond S, Bulliard JL, et al. Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries. Lancet Child Adolesc Health. 2022;6:409–31.
pubmed: 35468327
doi: 10.1016/S2352-4642(22)00095-5
Perme MP, Stare J, Esteve J. On estimation in relative survival. Biometrics. 2012;68:113–20.
pubmed: 21689081
doi: 10.1111/j.1541-0420.2011.01640.x
National Cancer Center. Cancer Registry and Statistics, Cancer Information Service, National Cancer Center, Japan. Cohort Life Table. 2018. https://ganjoho.jp/reg_stat/statistics/qa_words/cohort01.html .
Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359:1309–10.
pubmed: 11965278
doi: 10.1016/S0140-6736(02)08272-7
Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M, et al. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: a review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2020;55:681–94.
pubmed: 31636397
doi: 10.1038/s41409-019-0718-7
Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110:1397–400.
pubmed: 17475907
pmcid: 1939910
doi: 10.1182/blood-2007-03-081596
Bacigalupo A, Socie G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012;97:1142–8.
pubmed: 22315497
pmcid: 3409810
doi: 10.3324/haematol.2011.054841
Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, et al. Peripheral blood versus bone marrow from unrelated donors: bone marrow allografts have improved long-term overall and graft-versus-host disease-free, relapse-free survival. Biol Blood Marrow Transplant. 2019;25:270–8.
pubmed: 30292009
doi: 10.1016/j.bbmt.2018.09.004
Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, et al. The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. Bone Marrow Transplant. 2022;57:57–64.
pubmed: 34635798
doi: 10.1038/s41409-021-01479-4
Tsugane S. Why has Japan become the world’s most long-lived country: insights from a food and nutrition perspective. Eur J Clin Nutr. 2021;75:921–8.
pubmed: 32661353
doi: 10.1038/s41430-020-0677-5
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.
pubmed: 23245604
pmcid: 10790329
doi: 10.1016/S0140-6736(12)61728-0